ReNAgade Launches with $300M to More ... - Advanced Prostate...

Advanced Prostate Cancer

21,056 members26,262 posts

ReNAgade Launches with $300M to More Easily Deliver RNA Medicines

Scout4answers profile image
9 Replies

mRNA and Lipid nanoparticles. Science is on it's way to our rescue. It is hard not to be optimistic about the multi avenues in which science is taking aim at cancer.

While it was still in stealth, ReNAgade established a joint venture with fellow Massachusetts start-up Orna Therapeutics, which is advancing a portfolio of circular RNA therapeutics, combined with its own custom lipid nanoparticles, to achieve higher levels of protein expression.

In August 2022, Orna’s technology attracted Merck, which pumped a potential $3.5 billion into a development and commercialization pact for multiple oncology and infectious disease programs. This partnership includes technologies developed under Orna’s joint venture with ReNAgade, according to Tuesday’s press announcement.

Complete article;

biospace.com/article/renaga...

Written by
Scout4answers profile image
Scout4answers
To view profiles and participate in discussions please or .
Read more about...
9 Replies
NickJoy profile image
NickJoy

Blimey you are like a ninja with your research. Thank you for posting.

Nusch profile image
Nusch

Many thx 🙏

mypk profile image
mypk

I wish them luck, but sitting on a lot of money to start with attempts to develop mRNA anti-prostate cancer products doesn't guarantee success. For example CureVac's mRNA product CV9104 proved to be a failure after 10 years of development. See:

labiotech.eu/trends-news/cu...

And currently BionTech's mRNA product BNT112 apparently is going to follow CureVac's CV9104 fate.

Scout4answers profile image
Scout4answers in reply to mypk

There are no guarantees in life, save Death and Taxes

I Remain positive...

From Labiotech web site:

In 2012, we moved our therapies into Phase IIb based on interesting immunodata in Phase IIa studies, but we didn’t include checkpoint inhibitors because they weren’t available yet,” he says. “They are now, and we currently have a combined therapy that appears safe in animal models. We’re already planning with our partner, Boehringer Ingelheim, to start clinical trials of mRNA in combination with checkpoint inhibitors.”

mypk profile image
mypk in reply to Scout4answers

The "In 2012, we moved..." statement was actually made in 2017, if I'm not mistaken. And their new project with Boehringer Ingelheim, who initially contributed 35 million Euro to the NCT03164772 clinical trial project was canceled in 2021.

hopeful1956 profile image
hopeful1956

I love your positive attitude and optimism.

Scout4answers profile image
Scout4answers in reply to hopeful1956

Thanks ...The opposite is of no help to anyone.

j-o-h-n profile image
j-o-h-n

youtube.com/watch?v=Zqcf1r1...

Good Luck, Good Health and Good Humor.

j-o-h-n Wednesday 05/24/2023 12:31 PM DST

NotDFL profile image
NotDFL

Other companies such as Moderna and Pfizer are also developing mRNA based vaccines for cancers.

You may also like...

Xtandi + Zytiga Fails To Deliver

Rice University professor waits on FDA to approve what she hopes will be a cure for prostate cancer

company, Nanospectra Biosciences to develop the technology for commercial use. After a year, 13 out...

ONCT-534 some trial data soon?

DAARI molecule...

Re: \"The illusion of evidence based medicine\"

22, 2020), so it is odd to find a recycled article in the current issue of the BMJ. Dr. John...

Access to more research sci-hub

have access to whole text of research articles and scientific articles for free, adding sci-hub...